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Abstract Much of the beneficial effects of olive products
have been attributed to oleuropein. This study examined the
effects of oleuropein in rats with heart failure induced by per-
manent ligation of left coronary arteries. Twenty-four hours
after the operation, the rats were assigned to five groups in-
cluding a sham assigned to receive vehicle (1ml/day) and four
coronary ligated groups assigned to receive vehicle or
oleuropein at 5, 10, or 20 mg/kg/day. Five weeks later, echo-
cardiographic and hemodynamic parameters, serum concen-
trations of oxidative stress, and inflammatory markers were
determined. Myocardial infarction group receiving vehicle
showed impaired hemodynamic and echocardiographic pa-
rameters as evidenced by decreased left ventricular systolic
pressure, rate of rise and decrease of left ventricular pressure,
stroke volume, ejection fraction, and cardiac output. In addi-
tion, significant reduction in superoxide dismutase and gluta-
thione reductase was observed. Oleuropein treatment
prevented the reduction of these variables. Moreover, the
group had a significantly higher infarct size and serum
malondialdehyde, interleukin-1β, and tumor necrosis
factor-α than those of the sham group. Treatment with
oleuropein prevented the increase of these variables. The re-
sults show that oleuropein attenuates the progression of heart
failure, possibly by antioxidative and antiinflammatory
effects.
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Introduction
Heart failure, the inability to pump blood to meet the body’s
demand, is one of the most common causes of cardiovascular
morbidity and mortality, and its prevalence is rapidly increas-
ing (Gandhi et al. 2001; Sola et al. 2006). The most common
cause of heart failure is myocardial infarction, which initiates
a cascade of progressive structural and geometric changes in
the left ventricle leading to progressive inability of the heart to
maintain cardiac output.
Human and experimental models of heart failure are asso-
ciated with hemodynamic and echocardiographic changes in-
cluding progressive left ventricular dilation and increased left
ventricular end-diastolic pressure (LVEDP) (Mercanoglu et al.
2010; Parveen et al. 2011; Radovanovic et al. 2012). They are
also associated with decreased stroke volume (SV), fractional
shortening (FS), ejection fraction (EF), cardiac output (CO),
rate of rise of left ventricular pressure (+dp/dt), and rate of
decrease of left ventricular pressure (−dp/dt) (Mercanoglu
et al. 2010; Parveen et al. 2011; Radovanovic et al. 2012).
The pathogenesis and progression of heart failure have
been attributed to increased reactive oxygen species
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(Giordano 2005) and lipid peroxidation markers like
malondialdehyde (MDA). It has also been attributed to
decreased antioxidant defenses like superoxide dismutase
(SOD), catalase, and glutathione peroxidase (GPx) (Li
et al. 2012). Moreover, it has been related to increased
proinflammatory cytokines such as interleukin-1β (IL-
1β) and tumor necrosis factor-α (TNF-α) (Ertl and
Frantz 2005; Nian et al. 2004).
It has been reported that coronary heart disease, a major
contributor to heart failure, is not a major indicator of mortal-
ity in men living in areas whereMediterranean diets constitute
the major portions of their diets (Menotti et al. 1997). Olive
products constitute a major portion of Mediterranean diet
(Huang and Sumpio 2008). Much of the beneficial effects of
Mediterranean diets have been attributed to polyphenol com-
pounds (Andreadou et al. 2006; Huang and Sumpio 2008;
Keys 1980; Manna et al. 2004). A strong correlation has been
shown between the intake of foods rich in such compounds
and low mortality due to coronary heart disease (Andreadou
et al. 2006; Huang and Sumpio 2008; Keys 1980; Manna et al.
2004). Oleuropein, an important polyphenol of olive products,
has been reported to have beneficial effects such as
cardioprotective, antioxidant (Andreadou et al. 2006; Manna
et al. 2004), antiinflammatory (Kim et al. 2010), antiplatelet
(Omar 2010), and vasodilatory (Omar 2010). Moreover, we
(Janahmadi et al., 2015) previously showed that pretreatment
with oleuropein for 1 week prior to ligation of the coronary
artery offered cardioprotection in the setting of acute myocar-
dial infarction.
Given the beneficial effects of oleuropein, the present study
was designed to examine the effects of oleuropein on the pro-
gression of rat model of heart failure induced by permanent
ligation of the coronary artery. It also aimed to examine




Male Sprague-Dawley rats (200–250 g) were obtained from
Laboratory Animal Breeding Centre, Shiraz University of
Medical Sciences, Shiraz, Iran. They were maintained under
standard conditions (12-h light/dark cycle at 20–24 °C and
25–35% humidity) with standard rat chow and water ad
libitum.
Materials
Oleuropein was purchased from Serva (Feinbiochemica,
Heidelberg, Germany). Ketamine was obtained from
Rotexmedica (Trittau, Germany) and xylazine from Alfasan
(Woerden, Holland). Thiobutabarbital (Inactin®) was bought
from ByK Gulden (Konstanz, Germany).
Surgical procedures
Animals were anesthetized with intraperitoneal injections of
ketamine (60 mg/kg) and xylazine (8 mg/kg). They were then
tracheally intubated and ventilated by a rodent respirator (Ugo
Basile, Comerio, Italy) with room air at a frequency of 70
strokes/min and tidal volume of 1 ml/100 g body weight.
Body temperature was maintained at 37 ± 1 °C using a tem-
perature controller (Physitemp Instruments, Clifton, USA) by
means of a rectal probe. The chest cavity was opened at the
level of left fourth intercostal space, and the hearts were ex-
posed. The pericardial sacs were then opened, and left main
coronary arteries were ligated at 2–4 mm from their origins
using 5-0 prolene. In sham-operated rats, the sutures were
passed around the coronary arteries but were not tightened.
Afterwards, the chest walls and skin incisions were closed
using absorbable and nonabsorbable suture materials, respec-
tively (Janahmadi et al. 2015). The animals were then recov-
ered from anesthesia and kept in single cages under standard
conditions for 5 weeks, during which they were given daily
vehicle (1 ml distilled water), or oleuropein by oral gavage.
Experimental design
Starting from the next day after the operation, two groups
including a sham-operated group assigned to receive vehicle
(Sham-V) and a coronary artery-ligated group emerged. The
coronary artery-ligated group was further randomly divided
into four groups (n = 6–8) including a group assigned to re-
ceive vehicle (CAL-V) and three other groups assigned to
receive oleuropein at 5 mg/kg/day (CAL-Ole5), 10 mg/kg/
day (CAL-Ole10), or 20 mg/kg/day (CAL-Ole20).
Hemodynamic measurements
After 5 weeks of treatment with vehicle of oleuropein, the
animals were anesthetized with single intraperitoneal injec-
tions of thiobutabarbital (100 mg/kg). Heparinized saline-
filled catheters were inserted into left carotid arteries for the
measurement of systolic blood pressure (SBP), diastolic blood
pressure (DBP), and heart rate (HR).Moreover, catheters were
placed in right carotid arteries and advanced to left ventricles
for the measurement of left ventricular systolic pressure
(LVSP), LVEDP, and left ventricular +dp/dt and −dp/dt. The
animals were allowed to recover from surgical stress for
30 min, and then, measurements of the hemodynamic vari-
ables were performed using a PowerLab data acquisition sys-
tem (ML750, ADInstruments PowerLab System, Castle Hill,
Australia).
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Echocardiographic measurements
After the measurement of hemodynamic variables, the ani-
mals were subjected to transthoracic echocardiography using
a 10-5-MHz probe (Esaote, Florence, Italy). Two-dimensional
guided M-mode images of the left ventricle were obtained
from the short axis view at the level of papillary muscle.
Left ventricular internal diameter in diastole (LVIDd) and left
ventricular internal diameter in systole (LVIDs) were mea-
sured, and diastolic and diastolic volumes, SV, FS, EF, and
CO were calculated (see in the following).
After the measurement of echocardiographic variables,
blood samples were obtained and allowed to clot for 30 min.
The blood samples were then centrifuged at 1000g for 20 min,
and their serums were separated and stored at −80 °C until
analysis.
Assessment of infarct size
Cardiac infarct size was assessed as previously described
(Srikanth et al. 2009). The hearts were excised and washed
in ice-cold 0.9% saline and were embedded into parafilm.
After being kept at −4 °C for 1 h, they were cut transversely
into 2-mm-thick slices. The slices were then incubated with
1% TTC at 37 °C for 25 min. The stained slices were fixed
with 10% formaldehyde overnight. The infarct sizes were de-
termined via planimetry by using the NIH image software.
Measurements of serum biomarkers
Serum MDA (Bioassay Technology Laboratory, Shanghai,
China), TNF-α (Glory Science, Del Rio, TX, USA), and IL-
1β (Boster Biological Technology, Wuhan, China) levels
were measured by the ELISA method using the manufac-
turers’ instructions. Serum SOD and glutathione reductase
(GRx) were measured using chemical kits (Biorexfars,
Shiraz, Iran).
Calculations
Mean arterial pressure (MAP) was calculated as DBP plus one
third of arterial pulse pressure. Arterial resistance (AR) was
calculated as MAP/CO. Diastolic and systolic volumes were
calculated as 1.047[LVIDd]3 and 1.047[LVIDs]3, respective-
ly. SV was calculated as diastolic volume − systolic volume.
FS was calculated as [LVIDd − LVIDs] / LVIDd). EF was
calculated as stroke volume / diastolic volume and CO as
SV × HR.
Statistical analysis
Data, presented as mean ± SEM, were analyzed using one-
way analysis of variance (ANOVA) followed by Duncan’s
multiple range test for pairwise comparisons. A P value of
≤0.05 was considered statistically significant. The data were
analyzed using SigmaStat Statistical Software version 3.0
(San Jose, CA, USA). The illustrations were drawn using
the SigmaPlot software (version 8.0) (San Jose, CA, USA).
Results
Hemodynamic variables
SBP, LVSP, +dp/dt, and −dp/dt of the CAL-V group were
significantly lower than those of the Sham-V group.
However, AR and LVEDP of that group were significantly
higher than those of the Sham-V group (Table 1).
There were no significant differences between the SBP,
LVSP, +dp/dt, −dp/dt, or LVEDP of CAL-Ole5 and CAL-V
groups. However, SBP, LVSP, +dp/dt, and −dp/dt of CAL-
Ole10 and CAL-Ole20 groups were significantly higher than
those of the CAL-V group, while AR and LVEDPs of such
groups were significantly lower than those of the CAL-V
group. There was no significant difference between the DBP,
MAP, or HR of Sham-V, CAL-V, CAL-Ole5, CAL-Ole10,
and CAL-Ole20 groups (Table 1).
Echocardiographic variables
The LVIDs, LVIDd, systolic volume, and diastolic volume of
the CAL-V group were significantly higher than those of the
Sham-V group. However, SV, EF, FS, and CO of the CAL-V
group were significantly lower than those of the Sham-V
group. There were no significant differences between the
LVIDs, LVIDd, systolic and diastolic volumes, SV, EF, FS,
and CO of CAL-Ole5 and CAL-V groups. The LVIDs,
LVIDd, systolic volume, and diastolic volume of CAL-
Ole10 and CAL-Ole20 groups were significantly lower than
those of the CAL-V group. However, the SV, EF, FS, and CO
of CAL-Ole10 and CAL-Ole20 groups were significantly
higher than those of the CAL-V group (Table 2 and Fig. 1).
Infarct size
There was no significant difference between the infarct size of
CAL-Ole5 and CAL-V groups (Fig. 2). The infarct sizes of
CAL-Ole10 and CAL-Ole20 groups were significantly lower
than those of the CAL-V group.
Serum biomarkers
Serum levels of SOD and GRx of the CAL-V group were
significantly lower than those of the Sham-V group (Fig. 3).
There was no significant difference between the serum con-
centrations of SOD or GRx of CAL-Vand CAL-Ole5 groups.
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The serum concentrations of SOD and GRx of CAL-Ole10
and CAL-Ole20 groups were significantly higher than those
of the CAL-V group (Fig. 3).
Serum level of MDA of the CAL-V group was significant-
ly higher than that of the Sham-V group (Fig. 3). There was no
significant difference between the serum concentrations of
MDA of CAL-V and CAL-Ole5 groups. Serum MDA con-
centration of CAL-Ole10 and CAL-Ole20 groups was signif-
icantly lower than that of the CAL-V group (Fig. 3).
Serum levels of IL-1β and TNF-α of the CAL-V group
were significantly higher than those of the Sham-V group
(Fig. 4). There was no significant difference between
serum concentrations of IL-1β or TNF-α of CAL-V and
CAL-Ole5 groups. Serum concentrations of IL-1β or
TNF-α of CAL-Ole10 and CAL-Ole20 groups were sig-
nificantly lower than those of the CAL-V group (Fig. 4).
Discussion
The findings of the present study show that permanent ligation
of left main coronary results in heart failure and that
oleuropein offers cardioprotection in rats with heart failure
They also show that cardioprotection offered by oleuropein
Table 1 The values of hemodynamic parameters of all experimental groups
Sham-V CAL-V CAL-Ole5 CAL-Ole10 CAL-Ole20
SBP (mmHg) 125.5 ± 2.35 110.8 ± 2.4† 116.1 ± 2.9 119.7 ± 2.1‡ 122.4 ± 2.4‡
DBP (mmHg) 93.4 ± 2.5 88.9 ± 2.6 95.5 ± 2.7 94.3 ± 3.1 98.9 ± 2.4
MAP (mmHg) 104.3 ± 1.9 97.9 ± 2.4 102.1 ± 2.5 103.7 ± 2.5 106.2 ± 2.2
AR (mmHg/ml) 1.128 ± 0.087 1.579 ± 0.077† 1.268 ± 0.037‡ 1.196 ± 0.116‡ 1.190 ± 0.082‡
HR (beats/min) 411.9 ± 8.2 391.3 ± 11.7 396.1 ± 10.1 419.5 ± 10.8 399.2 ± 11.4
LVSP (mmHg) 134.3 ± 1.7 111.8 ± 2.7† 117.3 ± 2.6 124.9 ± 1.8‡ 127.2 ± 1.5‡
LVEDP (mmHg) −2.8 ± 0.2 4.5 ± 0.4† 3.7 ± 0.3 −0.2 ± 0.3‡ −2.5 ± 0.1‡
+dp/dt (mmHg/s) 5246 ± 212 3688 ± 115† 3803 ± 119 4474 ± 104‡ 5285 ± 87‡
−dp/dt (mmHg/s) −4398 ± 181 −2952 ± 81† −3204 ± 76 −3605 ± 114‡ −4153 ± 86‡
Data are shown as mean ± SEM, n = 6–8 each group
SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, AR arterial resistance, HR heart rate, LVSP left ventricular
systolic pressure, LVEDP left ventricular end-diastolic pressure, +dp/dt rate of rise of left ventricular pressure, −dp/dt rate of decrease of left ventricular
pressure, Sham-V sham group receiving vehicle (1 ml distilled water/day), CAL-V coronary artery-ligated group receiving vehicle, CAL-Ole5 coronary
artery-ligated group receiving oleuropein at 5 mg/kg/day, CAL-Ole10 coronary artery-ligated group receiving oleuropein at 10 mg/kg/day, CAL-Ole20
coronary artery-ligated group receiving oleuropein at 20 mg/kg/day
†Significant (p ≤ 0.05) difference from the Sham-V group; ‡Significant (p ≤ 0.05) difference from the CAL-V group
Table 2 The values of
echocardiographic parameters of
all experimental groups
Sham-V CAL-V CAL-Ole5 CAL-Ole10 CAL-Ole20
LVIDs (cm) 0.32 ± 0.02 0.80 ± 0.03† 0.79 ± 0.04 0.66 ± 0.04‡ 0.69 ± 0.02‡
LVIDd (cm) 0.64 ± 0.02 0.87 ± 0.02† 0.89 ± 0.03 0.79 ± 0.037 0.82 ± 0.02
SYS VOL (ml) 0.036 ± 0.01 0.54 ± 0.05† 0.53 ± 0.08 0.32 ± 0.06‡ 0.34 ± 0.03‡
DIAVOL (ml) 0.28 ± 0.03 0.70 ± 0.05† 0.75 ± 0.08 0.54 ± 0.08 0.58 ± 0.03
SV (ml) 0.24 ± 0.02 0.17 ± 0.01† 0.21 ± 0.01 0.22 ± 0.02‡ 0.24 ± 0.01‡
EF (%) 87.1 ± 1.9 23.7 ± 1.7† 30.18 ± 2.9 42.3 ± 3.1‡ 41.7 ± 2.5‡
FS (%) 50.4 ± 2.8 8.7 ± 0.7† 11.4 ± 1.2 16.9 ± 1.6‡ 16.4 ± 1.1‡
CO (ml/min) 95.7 ± 7.5 63.4 ± 3.1† 81.0 ± 3.2 91.1 ± 9.6‡ 93.8 ± 6.3‡
Data are shown as mean ± SEM, n = 6–8 each group
LVIDs left ventricular internal diameter in systole, LVIDd left ventricular internal diameter in diastole, SYS VOL
systolic volume,DIAVOL diastolic volume, SV stroke volume, EF ejection fraction, FS fractional shortening,CO
cardiac output, Sham-V sham-operated group receiving vehicle (1 ml distilled water/day),CAL-V coronary artery-
ligated group receiving vehicle, CAL-Ole5 coronary artery-ligated group receiving oleuropein at 5 mg/kg/day,
CAL-Ole10 coronary artery-ligated group receiving oleuropein at 10 mg/kg/day, CAL-Ole20 coronary artery-
ligated group receiving oleuropein at 20 mg/kg/day
†Significant (p ≤ 0.05) difference from the Sham-V group; ‡significant (p ≤ 0.05) difference from the CAL-V
group
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might be related to the oleuropein’s amelioration of oxidative
stress and release of proinflammatory cytokines.
In a previous study (Janahmadi et al. 2015), we showed
that oleuropein, given as pretreatment for 1 week prior to
ligation of the coronary artery, was able to offer protection
against acute myocardial infarction. The study showed that
oleuropein cardioprotection might be mediated by reduction
of oxidative stress and proinflammatory cytokines. The pres-
ent study aimed to examine the treatment effects of oleuropein
on the progression of heart failure. The hemodynamic and
echocardiographic findings of the present study show that
permanent ligation of the coronary artery for 5 weeks results
in heart failure. Our study shows that cardiac hemodynamic
parameters including LVSP, +dp/dt, and −dp/dt were
significantly lower, and LVEDP was higher in coronary
artery-ligated group receiving vehicle than in sham-operated
group. Such findings are similar to those of previous studies
using the same model (Huang et al. 2009) or other models
(Garjani et al. 2011) of experimental as well as human
(Aurigemma et al. 2006) heart failure. Moreover, echocardio-
graphic assessments showed that LVIDs, LVIDd, systolic vol-
ume, and diastolic volume of coronary artery-ligated rats re-
ceiving vehicle were significantly higher, while SV, EF, FS,
and CO of that group were significantly lower than those of
the sham-operated group. The echocardiographic findings are
similar to those of earlier studies on experimental (Huang et al.
2009; Mercanoglu et al. 2010; Zhang et al. 2014; Zhou et al.
2007) and clinical (Radovanovic et al. 2012) heart failure.
Fig. 2 a Infarct size (as a
percentage of the left ventricle) of
coronary artery-ligated groups and
b representative photographs of
myocardial slices from sham-
operated and coronary artery-
ligated groups. Sham-V sham group
receiving vehicle (1 ml distilled
water/day), CAL-V coronary artery-
ligated group receiving vehicle
(1 ml distilled water/day), CAL-
Ole-5 coronary artery-ligated group
receiving oleuropein at 5 mg/kg/
day, CAL-Ole10 coronary artery-
ligated group receiving oleuropein
at 10 mg/kg/day, CAL-Ole20
coronary artery-ligated group
receiving oleuropein at 20 mg/kg/
day. Data are shown as
mean ± SEM, n = 6–8 each group.




Two-dimensional, upper plane, and
M-mode, lower plane, short-axis
views of left ventricle at the level of
papillary muscles of all
experimental groups. Sham-V
sham-operated group receiving
vehicle (1 ml distilled water/day),
CAL-V coronary artery-ligated
group receiving the vehicle, CAL-
Ole10 coronary artery-ligated group
receiving oleuropein at 10 mg/kg/
day, CAL-Ole20 coronary artery-
ligated group receiving oleuropein
at 20 mg/kg/day
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The progressive worsening of heart failure has been attrib-
uted to a number of mechanisms including the increase of
oxidative stress (Giordano 2005), release of proinflammatory
cytokines (Bozkurt et al. 2010), and neurohormonal activation
(McAlpine et al. 1988). We, therefore, measured the serum
concentrations of indices of oxidative stress such as SOD,
GRx and MDA and proinflammatory cytokines such as IL-
1β and TNF-α. Serum concentration of markers of oxidative
stress and proinflammatory cytokines can predict the severity
of heart failure as they were correlated with the severity of it
(Wojciechowska et al. 2014; Zarrouk-Mahjoub et al. 2016).
Our findings show that the present model of heart failure is
associated with increased oxidative stress and release of pro-
inflammatory cytokines. It has been suggested that oxidative
stress via numerous mechanisms such as direct cytotoxic and
negative inotropic (Ferrari et al. 1998), cytokine-stimulating
(Mak and Newton 2001), and apoptotic (Kumar et al. 2002)
effects contributes to the development of heart failure.
Moreover, the contribution of proinflammatory cytokines to
the development of the disease has been related to their ability
to directly affect cardiac structure and contractile function
(Hegewisch et al. 1990; Klug et al. 1993).
Oleuropein, at two largest doses of 10 and 20 mg/kg/day,
attenuated the decrease of SBP, LVSP, +dp/dt, and −dp/dt and
Fig. 3 Serum levels of
biomarkers of oxidative stress of
all experimental groups. Sham-V
sham-operated group receiving
vehicle (1 ml distilled water/day),
CAL-V coronary artery-ligated
group receiving vehicle, CAL-
Ole-5 coronary artery-ligated
group receiving oleuropein at
5 mg/kg/day, CAL-Ole10
coronary artery-ligated group
receiving oleuropein at 10 mg/kg/
day, CAL-Ole20 coronary artery-
ligated group receiving
oleuropein at 20 mg/kg/day. Data
are shown as mean ± SEM, n = 6–
8 each group. †Significant
difference (p ≤ 0.05) from Sham-
V. ‡Significant difference
(p ≤ 0.05) from CAL-V
Fig. 4 Serum levels of proinflammatory cytokines of all experimental
groups. Sham-V sham-operated group receiving vehicle (1 ml distilled
water/day), CAL-V coronary artery-ligated group receiving vehicle,
CAL-Ole5 coronary artery-ligated group receiving oleuropein at
5 mg/kg/day, CAL-Ole10 coronary artery-ligated group receiving
oleuropein at 10 mg/kg/day, CAL-Ole20 coronary artery-ligated group
receiving oleuropein at 20 mg/kg/day. Data are shown as mean ± SEM,
n = 6–8 each group. †Significant difference (p ≤ 0.05) from Sham-V.
‡Significant difference (p ≤ 0.05) from CAL-V
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the increase of LVEDP and infarct size in coronary artery-
ligated rats. It also prevented the increase of LVIDs, LVIDd,
systolic volume, and diastolic volume and the decrease of SV,
EF, FS, and CO in such rats. These findings show that
oleuropein at the two latter doses has cardioprotective effects.
Such a conclusion receives support from previous studies
demonstrating that oleuropein was cardioprotective against
acute and chronic doxorubicin-induced cardiotoxicities
(Andreadou et al. 2014; Andreadou et al. 2007) and
ischemia-reperfusion injuries (Andreadou et al. 2006).
The cardioprotective effects of oleuropein have been attrib-
uted to several mechanisms such as reduction of oxidative and
nitrosative stress (Andreadou et al. 2007) as well as antiplate-
let (Petroni et al. 1995), hypolipidemic (Andreadou et al.
2006), and antiinflammatory (Andreadou et al. 2014) activi-
ties. We, therefore, sought to measure serum levels of SOD,
GRx, MDA, IL-1β, and TNF-α to examine the role of oxida-
tive stress and proinflammatory cytokines in the oleuropein’s
cardioprotective effects. Our findings show that oleuropein
reduces proinflammatory cytokines and increased antioxidant
markers. Such findings are similar to those that reported that
oleuropein reduced prooxidants and proinflammatory cyto-
kines and increased antioxidant markers in adriamycin
cardiotoxicity (Andreadou et al. 2014; Andreadou et al.
2007) and myocardial ischemia/reperfusion (Andreadou
et al. 2006; Manna et al. 2004) studies.
Hemodynamically speaking, part of the beneficial ef-
fects of oleuropein might be related to its hypotensive and
vasodilatory effects. We (Nekooeian et al. 2014) and
others (Romero et al. 2016; Zarzuelo et al. 1991) showed
that oleuropein possessed hypotensive and vasodilatory
effects. It is interesting that, nonetheless, treatment with
oleuropein was associated with increased SBP in the pres-
ent model of heart failure, which was associated with
reduced SBP and increased AR. The possible explanation
for such an effect is that oleuropein, by virtue of its
vasodilating activity, reduced AR and afterload. The re-
duced afterload may have helped that failing heart to
function effectively and increase CO and consequently
SBP. This explanation is in agreement with the most re-
cent guidelines on the effectiveness of the use of vasodi-
lators in the management of human heart failure (Yancy
et al. 2013).
Taken together, our findings receive support from and give
support to the widely accepted belief that Mediterranean diets,
by virtue of richness in olive products, are associated with
lower morbidity and mortality due to coronary heart diseases
(Keys 1997). Given the role of coronary heart diseases in the
initiation and progression of heart failure, our findings may be
of clinical and practical relevance. Our findings may lay the
ground for subsequent studies of oleuropein in other animal
models of the disease and human heart failure and future use
of the compound in the setting of human heart failure.
One limitation of the present study was the absence of a
group of sham-operated rats receiving oleuropein diet. The
presence of such a group could provide a chance to compare
the effects of oleuropein in sham-operated and heart failure
rats.
In conclusion, the findings of the present study indicate that
oleuropein is cardioprotective in rats with heart failure, and
such an effect might be mediated by antioxidant and
antiinflammatory activities.
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